公开(公告)号：US20240216342A1

公开(公告)日：2024-07-04

申请号：US18556912

申请日：2022-04-27

Applicant: KOWA COMPANY, LTD.

Inventor： Ryohei TANIGAWA ,  Ayumi SAITO ,  Kaho IKEGAMI

IPC: A61K31/423 ,  A61K31/205 ,  A61P3/00

CPC classification number: A61K31/423 ,  A61K31/205 ,  A61P3/00

Abstract: Provided is a novel preventing and/or treating agent useful for prevention and/or treatment of carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect. The present invention relates to a medicament for preventing and/or treating carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect, the medicament comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

公开(公告)号：US20240277745A1

公开(公告)日：2024-08-22

申请号：US18564115

申请日：2022-05-25

Applicant: KOWA COMPANY, LTD

Inventor： Noboru KANETA ,  Ryu OSHIMA ,  Shona Sanchita PENDSE ,  Ryohei TANIGAWA

IPC: A61K31/7048 ,  A61K31/423 ,  A61P1/16

CPC classification number: A61K31/7048 ,  A61K31/423 ,  A61P1/16

Abstract: Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.

公开(公告)号：US20200046686A1

公开(公告)日：2020-02-13

申请号：US16609249

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61P1/16

Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient.The present invention relates to the use of pemafibrate in a liver cirrhosis patient.More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

公开(公告)号：US20180250274A1

公开(公告)日：2018-09-06

申请号：US15903279

申请日：2018-02-23

Applicant: KOWA COMPANY, LTD.

Inventor： Mitsumasa NAKAMURA ,  Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61K31/575 ,  A61P1/16

CPC classification number: A61K31/423 ,  A61K31/575 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.